Clopidogrel resistance is common in patients undergoing vascular and coronary interventions.

Objectives: "Clopidogrel resistance," also defined as heightened platelet reactivity (HPR) while on clopidogrel therapy, may lead to a sub-optimal antiplatelet effect and a potential thrombotic event. There is limited literature addressing the prevalence of HPR in a large cohort of patients receiving either coronary or endovascular interventions.

Methods: In a large integrated healthcare system, patients with a P2Y12 reaction units (PRU) test were identified.